CNBC's Meg Tirrell reports on the victory for Biogen in its patent case over its Multiple Sclerosis drug. » Read More
After an experimental painkiller designed to be safer to use has outperformed in testing, Nektar Therapeutics is exploring next steps. » Read More
By: Robert Ferris
A new study finds that poison control centers across the U.S. field 32 calls a day from families with a child who has been exposed to opioids. » Read More
Alex Gorsky, CEO of Johnson & Johnson, talks about the opportunities available in the Chinese healthcare space and US-China relations. » Read More
Alex Gorsky, CEO of Johnson & Johnson, says it's important that the number of those uninsured stays at a low figure.
Johnson & Johnson CEO Alex Gorsky spoke with CNBC about health care from the China Development Forum in Beijing.
CNBC's Meg Tirrell reports on what the 2017 budget blueprint could mean for the health care industry.
The musical features a number of absurd things about the notorious provocateur Shkreli, many of which happen to be true.
Large companies have gotten carried away with price increases and financial engineering, making smaller names more attractive, says Brad Loncar of the Loncar Cancer Immunotherapy ETF.
Valeant's stock dropped Tuesday, after news surfaced Monday that the billionaire hedge fund manager sold his remaining shares.
Valeant plunges following Bill Ackman's decision to sell his entire position. Discussing the potential ripple effect for hedge funds with Bethany McLean, Vanity Fair contributing editor, and Herb Greenberg, Pacific Square Research.
Valeant sinks as Pershing Square's Bill Ackman throws in the towel. Karen Firestone, Aureus Asset Management, and Kourtney Gibson, Loop Capital president, weigh in.
CNBC's Leslie Picker takes a look at Bill Ackman's stock-picking history, including winners and losers.
"Fast Money Halftime Report" trader Josh Brown weighs in on Valeant, as the stock plunges following Bill Ackman's decision to sell his entire stake.
CNBC's Meg Tirrell takes a closer look at President Trump's FDA pick Dr. Scott Gottlieb, and what this nomination means for the health care sector. With “Fast Money Halftime Report” traders.
The bill could overturn a nondiscrimination law known as GINA as well as the American Disabilities Act, STAT reports.
The best-performing large-cap ETF is enjoying an incredible comeback in 2017.
China's Shanghai Fosun Pharmaceutical is planning a bid for German generic drugmaker Stada.
Promising new research suggests that marijuana could be used to treat Alzheimer's, but there's a major roadblock: the federal government.
Biotech stocks might be in a slump, but there's an upside, one analyst says.
Get the best of CNBC in your inbox